Partial prevention of glucocorticoid-induced osteocyte deterioration in young male mice with osteocrin gene therapy

C-type natriuretic peptide facilitates autonomic Ca2+ entry in growth plate chondrocytes for stimulating bone growth

(2022) Yuu Miyazaki et al.   eLife

Mechanical load regulates bone growth via periosteal Osteocrin

(2021) Haruko Watanabe-Takano et al.   Cell Reports

Control of osteocyte dendrite formation by Sp7 and its target gene osteocrin

(2021) Jialiang S. Wang et al.   Nature Communications

Male mice with elevated C-type natriuretic peptide-dependent guanylyl cyclase-B activity have increased osteoblasts, bone mass and bone strength

(2020) Jerid W. Robinson et al.   BONE

A FAK/HDAC5 signaling axis controls osteocyte mechanotransduction

(2020) Tadatoshi Sato et al.   Nature Communications

Denosumab vs risedronate in glucocorticoid-induced osteoporosis: final results of a 24-month randomized, double-blind, double-dummy trial

(2019) Kenneth G. Saag et al.   Arthritis & Rheumatology

C-Type Natriuretic Peptide Analogue Therapy in Children with Achondroplasia

(2019) Ravi Savarirayan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Regulation of sclerostin in glucocorticoid-induced osteoporosis (GIO) in mice and humans

(2019) Sylvia Thiele et al.   Endocrine Connections

Genome-wide association study of extreme high bone mass: Contribution of common genetic variation to extreme BMD phenotypes and potential novel BMD-associated genes

(2018) Celia L. Gregson et al.   BONE

Strain-specific differences in the development of bone loss and incidence of osteonecrosis following glucocorticoid treatment in two different mouse strains

(2018) Kie Shidara et al.   Journal of Orthopaedic Translation

Glucocorticoid-Induced Osteoporosis

(2018) Lenore Buckley et al.   NEW ENGLAND JOURNAL OF MEDICINE

Circulating osteocrin stimulates bone growth by limiting C-type natriuretic peptide clearance

(2017) Yugo Kanai et al.   JOURNAL OF CLINICAL INVESTIGATION

Glucocorticoid suppression of osteocyte perilacunar remodeling is associated with subchondral bone degeneration in osteonecrosis

(2017) Tristan W. Fowler et al.   Scientific Reports

Osteocyte-Intrinsic TGF-β Signaling Regulates Bone Quality through Perilacunar/Canalicular Remodeling

(2017) Neha S. Dole et al.   Cell Reports

Cortical bone loss caused by glucocorticoid excess requires RANKL production by osteocytes and is associated with reduced OPG expression in mice

(2016) Marilina Piemontese et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

SIKs control osteocyte responses to parathyroid hormone

(2016) Marc N. Wein et al.   Nature Communications

Strain dependent differences in glucocorticoid-induced bone loss between C57BL/6J and CD-1 mice

(2016) Adel Ersek et al.   Scientific Reports

The Wnt Inhibitor Sclerostin Is Up-regulated by Mechanical Unloading in Osteocytesin Vitro

(2015) Jordan M. Spatz et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Epidemiology and postoperative outcomes of atypical femoral fractures in older adults: A systematic review

(2015) Kareeann S. F. Khow et al.   Journal of Nutrition Health & Aging

Diagnosis and Management of Osteonecrosis of the Jaw: A Systematic Review and International Consensus

(2014) Aliya A Khan et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Selective glucocorticoid receptor modulation maintains bone mineral density in mice

(2012) Sylvia Thiele et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Glucocorticoid dose determines osteocyte cell fate

(2011) Junjing Jia et al.   FASEB JOURNAL

Glucocorticoids Suppress Bone Formation by Attenuating Osteoblast Differentiation via the Monomeric Glucocorticoid Receptor

(2010) Alexander Rauch et al.   Cell Metabolism

Guidelines for assessment of bone microstructure in rodents using micro-computed tomography

(2010) Mary L Bouxsein et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: Thirty-six-month results of a randomized, double-blind, controlled trial

(2009) Kenneth G. Saag et al.   ARTHRITIS AND RHEUMATISM

Once-Weekly Oral Alendronate 70 mg in Patients with Glucocorticoid-Induced Bone Loss: A 12-Month Randomized, Placebo-Controlled Clinical Trial

(2009) S. A. STOCH et al.   JOURNAL OF RHEUMATOLOGY

Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial

(2009) David M Reid et al.   LANCET

The glucocorticoid receptor and FOXO1 synergistically activate the skeletal muscle atrophy-associated MuRF1 gene

(2008) David S. Waddell et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

Glucocorticoid excess in mice results in early activation of osteoclastogenesis and adipogenesis and prolonged suppression of osteogenesis: A longitudinal study of gene expression in bone tissue from glucocorticoid-treated mice

(2008) Wei Yao et al.   ARTHRITIS AND RHEUMATISM

Analysis of AAV Serotypes 1–9 Mediated Gene Expression and Tropism in Mice After Systemic Injection

(2008) Carmela Zincarelli et al.   MOLECULAR THERAPY